REPLY
Reply, a global systems integrator and consulting firm and Oracle Cloud Managed Service Provider, has received 4 Oracle Partner awards in recognition of its capabilities to deliver pioneering solutions, drive business value and customers success. The EMEA Cluster Partner Awards, announced at the Oracle EMEA Partner Appreciation Reception during Oracle CloudWorld in Las Vegas, have been awarded to the Reply companies specialized on Oracle technologies; Healthy Reply, Nimbus Reply and Red Reply.
The awards celebrate partners that foster innovation, accelerate business growth and create value to enable success for customers through technology integration and services built on Oracle Cloud Application, Oracle Cloud Infrastructure and Oracle Database technology. The Reply companies, focused on Oracle Cloud Infrastructure solutions and experts in end-to-end Oracle solutions, received the following EMEA Cluster Partner Awards:
- 2023 Customer Success Partner of Year – Europe South Tech / Cloud has been given to Nimbus Reply for the high customer satisfaction they have earned by empowering customers with innovative multi-cloud solutions. These resulted in a reduction of operational costs, an increase in application performance and improvements in system scalability, all while considering critical regulatory requirements.
- 2023 Customer Success Partner of Year – Europe North & East Tech / Cloud has been awarded to Red Reply for their capabilities to increase value to their end customers by streamlining solution implementation and management, improving human capital efficiency, reducing costs, minimizing technical debt, and achieving a measurable return on investment.
- 2023 Business Impact Partner of Year – Europe South Apps / SaaS has been assigned to Healthy Reply for developing exceptional solutions based on Oracle SaaS for the healthcare industry. The solutions developed allow to expedite projects and maximise the benefits of Cloud releases resulting invaluable for clients in managing specific processes and integrating with healthcare national systems.
- 2023 Innovation Partner of Year – Europe North & East Tech / Cloud has been granted to Red Reply for their capabilities to create pioneering solutions that empower customers and support these meeting their business goals and challenges. Red Reply have developed a solution that enables companies to seamlessly migrate their Legacy applications to the Cloud quickly. This rapid migration not only results in immediate cost savings but also enhances the company’s operational efficiency. Additionally, the system allows the transformation of Legacy Applications into Cloud-based Software-as-a-Service (SaaS) through a fully managed service, thus eliminating the need for extensive in-house development resources.
Filippo Rizzante, CTO at Reply, said, “We are delighted to have won these awards that reflect our continuous commitment in delivering cutting-edge Oracle solutions. Our ongoing investments in innovation and research & development, together with the expertise and capabilities of our companies dedicated to Oracle technologies allow us to support our customers better and to get the most from Oracle solutions.”
Reply, Oracle partner since 1997, with its companies dedicated to Oracle technologies, is best in class in Oracle Cloud Computing. With over 1500 certifications Oracle, Reply owns and manages one of the main European centers of competence. Reply is able to combine the full coverage of the entire supply chain, has experience in Oracle application suites, in Oracle technologies and in the main Oracle vertical solutions for the industry.
More information about Reply and Oracle partnership here.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Healthy Reply
Healthy Reply is the Reply Group company specialising in telemedicine, telemonitoring and the continuity of social welfare. Healthy Reply collaborates with public and private healthcare institutions and bodies, clinics and hospitals, social and healthcare facilities, insurance companies and banks, convention centres and enterprises, to design customised services that can guarantee continuous care and assistance. Healthy Reply has established strong competencies in Oracle ERPM Cloud solutions and continue to invest in expanding its offerings across all Oracle SaaS solutions.
Nimbus Reply
Nimbus Reply is the Reply Group company specialising in the delivery of Multi-Cloud solutions for the Health and Public Sector market. Composed of specialists with expertise in several Cloud Service Providers, Nimbus Reply promotes the adoption and evolution of the Cloud paradigm in the Public Sector, supporting end-to-end customers in the Journey to Multi-Cloud, in a Cloud Continuum perspective.
Red Reply
Red Reply is the Reply Group company specialising in Oracle Cloud Infrastructure with a focus on IaaS and PaaS solutions and offers Cloud Strategy and Migration, Application Development, Cloud / Application Management and Operations services. Red Reply is an expert in end-to-end Oracle solutions and one of first Oracle Cloud Managed Service Providers (MSP) in Europe. www.red.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919738958/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release
Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom